Gangliosides inhibit the release of interleukin-1beta in amyloid beta-protein-treated human monocytic cells.
Amyloid-beta protein (A beta) is known to induce microglial activation with concomitant release of cytokines. Gangliosides have documented neuritogenic and neurotrophic properties. We determined the effects of A beta on the release of interleukin-1beta (IL-1beta) from the human monocytic cell line, THP-1 cells. A beta 1-42 significantly induced the release of IL-1beta from the cells. A beta 1-40, A beta 40-1, A beta 1-38, and A beta precursor protein (beta-APP) analogs also released a small amount of IL-1beta. A beta 1-42-activated cells demonstrated approx an 18-fold higher IL-1beta release than that for control cells or A beta 1-40 (soluble; S) treated cells. The release of IL-1beta from A beta 1-42-activated cells was significantly inhibited (33-48% of activated cells; p < 0.05 for the control value) by addition of gangliosides, suggesting that gangliosides inhibit the continuous cycle of the IL-1beta production in THP-1 cells.
Ariga
T
T
Clinical Research Center, Eisai Co. Ltd., Tokyo, Japan. t-ariga@hhc.eisai.co.jp
Kiso
M
M
Hasegawa
A
A
Miyatake
T
T
D016229:Amyloid beta-Peptides / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D005732:Gangliosides / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism*; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D011487:Protein Conformation; D013997:Time Factors
D016229:Amyloid beta-Peptides; D005732:Gangliosides; D007375:Interleukin-1